

Walpole

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	27.1	77.4	(47.9-118.3)	Male	19	16.9	112.4	(67.6-175.5)
Female	12	9.7	123.1	(63.5-215.0)	Female	18	13.0	139.0	(82.3-219.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	5.1	98.3	(31.7-229.3)	Male	1	4.2	nc	(nc-nc)
Female	6	4.1	146.8	(53.6-319.6)	Female	6	3.1	194.5	(71.0-423.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.9	nc	(nc-nc)	Male	16	14.5	110.6	(63.2-179.6)
Female	96	94.2	102.0	(82.6-124.5)	Female	7	12.5	55.9	(22.4-115.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.9	nc	(nc-nc)	Male	8	10.3	77.5	(33.4-152.7)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	31	38.1	81.4	(55.3-115.5)	Female	14	9.8	142.7	(77.9-239.4)
Female	35	35.5	98.6	(68.6-137.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	8	8.2	97.6	(42.0-192.3)
Male	6	7.0	85.2	(31.1-185.5)	Female	2	8.4	nc	(nc-nc)
Female	0	1.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	97	100.6	96.4	(78.2-117.6)
Male	3	2.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.5	nc	(nc-nc)	Male	9	6.3	143.4	(65.4-272.2)
<u>Kidney & Renal Pelvis</u>					Female	3	3.9	nc	(nc-nc)
Male	25	12.8	194.8	(126.1-287.6)	<u>Testis</u>				
Female	6	7.6	78.6	(28.7-171.1)	Male	3	3.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	4.3	nc	(nc-nc)	Male	5	4.3	116.6	(37.6-272.0)
Female	0	1.1	nc	(nc-nc)	Female	13	12.3	105.8	(56.3-180.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	8.9	nc	(nc-nc)	Female	20	21.0	95.3	(58.2-147.2)
Female	6	6.8	88.0	(32.2-191.6)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	333	358.9	92.8	(83.1-103.3)
Male	3	6.2	nc	(nc-nc)	Female	325	330.1	98.4	(88.0-109.8)
Female	2	2.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	46	50.2	91.7	(67.1-122.3)					
Female	55	46.5	118.2	(89.0-153.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Waltham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	43	60.0	71.6	(51.8-96.5)	Male	26	38.1	68.3	(44.6-100.1)
Female	22	23.4	94.2	(59.0-142.7)	Female	27	32.4	83.3	(54.9-121.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	11.5	69.4	(29.9-136.8)	Male	8	9.4	85.5	(36.8-168.5)
Female	9	9.9	91.0	(41.5-172.8)	Female	7	7.4	94.9	(38.0-195.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.9	nc	(nc-nc)	Male	33	32.5	101.4	(69.8-142.4)
Female	229	219.9	104.1	(91.1-118.5)	Female	34	30.3	112.4	(77.8-157.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	8	9.8	81.6	(35.1-160.8)	Male	29	22.6	128.3	(85.9-184.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	69	83.9	82.2	(64.0-104.1)	Female	26	23.4	111.3	(72.7-163.1)
Female	104	84.6	123.0	(100.5-149.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	23	18.0	127.5	(80.8-191.3)
Male	11	15.5	71.1	(35.4-127.2)	Female	18	20.1	89.6	(53.1-141.6)
Female	8	4.5	176.9	(76.2-348.6)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	213	221.6	96.1	(83.6-109.9)
Male	6	6.1	98.0	(35.8-213.3)	<u>Stomach</u>				
Female	4	4.8	nc	(nc-nc)	Male	12	13.8	86.7	(44.8-151.5)
<u>Kidney & Renal Pelvis</u>					Female	13	9.3	140.2	(74.6-239.8)
Male	20	28.1	71.1	(43.4-109.9)	<u>Testis</u>				
Female	14	18.2	76.9	(42.0-129.1)	Male	9	11.2	80.4	(36.7-152.7)
<u>Larynx</u>					<u>Thyroid</u>				
Male	9	9.6	94.1	(43.0-178.7)	Male	8	10.1	78.9	(34.0-155.5)
Female	3	2.7	nc	(nc-nc)	Female	29	31.5	92.0	(61.6-132.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	10	20.1	49.7	(23.8-91.4)	Female	41	49.3	83.2	(59.7-112.9)
Female	19	16.3	116.7	(70.2-182.3)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	707	799.1	88.5	(82.1-95.2)
Male	12	13.7	87.8	(45.3-153.4)	Female	787	788.7	99.8	(92.9-107.0)
Female	8	5.0	160.5	(69.1-316.2)					
<u>Lung and Bronchus</u>									
Male	102	110.8	92.0	(75.0-111.7)					
Female	88	111.7	78.8	(63.2-97.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ware

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	11.7	51.4	(18.8-111.8)	Male	6	7.1	84.5	(30.8-183.9)
Female	5	4.6	108.4	(34.9-252.9)	Female	5	5.9	85.3	(27.5-199.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.1	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	2	6.1	nc	(nc-nc)
Female	31	41.7	74.4	(50.5-105.6)	Female	4	5.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	1.7	nc	(nc-nc)	Male	5	4.4	114.5	(36.9-267.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	20	16.3	122.6	(74.9-189.4)	Female	7	4.4	157.4	(63.1-324.3)
Female	10	17.0	58.7	(28.1-107.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	3.5	nc	(nc-nc)
Male	1	3.0	nc	(nc-nc)	Female	0	4.0	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	34	43.3	78.6	(54.4-109.9)
Male	1	0.9	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.8	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.9	nc	(nc-nc)
Male	3	5.4	nc	(nc-nc)	<u>Testis</u>				
Female	2	3.5	nc	(nc-nc)	Male	3	1.5	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	1.9	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	4	5.3	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	3.8	nc	(nc-nc)	Female	9	9.3	96.9	(44.2-183.9)
Female	1	3.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	126	153.3	82.2	(68.5-97.8)
Male	3	2.7	nc	(nc-nc)	Female	120	151.2	79.4	(65.8-94.9)
Female	2	1.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	21	21.5	97.6	(60.4-149.3)					
Female	18	21.7	83.1	(49.2-131.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wareham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	24	27.3	88.0	(56.4-131.0)	Male	15	16.2	92.5	(51.8-152.6)
Female	13	10.0	130.6	(69.5-223.4)	Female	5	12.9	38.7	(12.5-90.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	4.7	126.4	(46.2-275.2)	Male	4	4.2	nc	(nc-nc)
Female	3	4.0	nc	(nc-nc)	Female	2	3.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.9	nc	(nc-nc)	Male	9	13.9	64.7	(29.5-122.8)
Female	91	94.4	96.4	(77.6-118.3)	Female	14	12.7	110.3	(60.3-185.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	3.8	130.0	(41.9-303.4)	Male	12	10.0	119.8	(61.8-209.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	54	37.7	143.2	(107.6-186.8)	Female	8	9.9	81.0	(34.9-159.7)
Female	41	35.4	115.9	(83.1-157.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	11	8.2	133.8	(66.7-239.4)
Male	10	7.1	141.8	(67.9-260.7)	Female	11	8.5	129.2	(64.4-231.2)
Female	1	1.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	99	104.3	94.9	(77.1-115.5)
Male	2	1.9	nc	(nc-nc)	<u>Stomach</u>				
Female	3	1.6	nc	(nc-nc)	Male	5	6.2	80.9	(26.1-188.7)
<u>Kidney & Renal Pelvis</u>					Female	4	3.8	nc	(nc-nc)
Male	22	12.5	175.7	(110.1-266.0)	<u>Testis</u>				
Female	9	7.8	115.1	(52.5-218.6)	Male	3	3.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	7	4.4	158.8	(63.6-327.2)	Male	3	3.9	nc	(nc-nc)
Female	3	1.2	nc	(nc-nc)	Female	9	12.1	74.5	(34.0-141.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	10	8.6	116.3	(55.7-214.0)	Female	22	21.6	102.0	(63.9-154.4)
Female	3	6.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	401	358.4	111.9	(101.2-123.4)
Male	10	6.1	163.5	(78.3-300.7)	Female	337	333.1	101.2	(90.6-112.6)
Female	3	2.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	64	51.0	125.5	(96.7-160.3)					
Female	55	48.6	113.1	(85.2-147.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Warren

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	5.5	90.7	(29.2-211.6)	Male	1	3.5	nc	(nc-nc)
Female	0	1.8	nc	(nc-nc)	Female	6	2.6	228.0	(83.3-496.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.0	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	2.9	nc	(nc-nc)
Female	19	18.5	102.8	(61.8-160.5)	Female	4	2.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.8	nc	(nc-nc)	Male	0	2.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	7	7.8	90.1	(36.1-185.6)	Female	1	1.9	nc	(nc-nc)
Female	7	6.6	106.5	(42.6-219.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	1.7	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	13	21.5	60.5	(32.2-103.5)
Male	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
Female	2	0.4	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.7	nc	(nc-nc)
Male	1	2.6	nc	(nc-nc)	<u>Testis</u>				
Female	4	1.5	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.9	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	3	2.6	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.8	nc	(nc-nc)	Female	4	4.2	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	47	74.4	63.2	(46.4-84.0)
Male	0	1.3	nc	(nc-nc)	Female	74	64.1	115.4	(90.6-144.9)
Female	0	0.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	5	10.3	48.3	(15.6-112.8)					
Female	14	8.9	156.6	(85.5-262.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Warwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.8	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	3.0	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	1.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	0.3	nc	(nc-nc)
Male	1	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	2	3.3	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.3	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	9	11.5	78.2	(35.7-148.5)
Male	1	0.2	nc	(nc-nc)	Female	4	9.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	1	1.6	nc	(nc-nc)					
Female	0	1.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Washington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.6	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	2.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	0.9	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	3	2.5	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.2	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	7	8.4	83.0	(33.2-171.0)
Male	0	0.2	nc	(nc-nc)	Female	5	6.6	75.3	(24.3-175.7)
Female	0	0.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	1	1.1	nc	(nc-nc)					
Female	0	0.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Watertown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	50	38.1	131.4	(97.5-173.2)	Male	9	22.7	39.6	(18.1-75.1)
Female	15	16.5	90.9	(50.9-150.0)	Female	19	21.2	89.8	(54.0-140.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	6.6	nc	(nc-nc)	Male	2	5.8	nc	(nc-nc)
Female	4	6.3	nc	(nc-nc)	Female	2	5.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.2	nc	(nc-nc)	Male	15	19.5	76.8	(42.9-126.6)
Female	134	144.6	92.7	(77.7-109.8)	Female	21	20.8	100.7	(62.3-154.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	6.3	79.7	(25.7-185.9)	Male	9	13.0	69.1	(31.5-131.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	43	52.0	82.7	(59.9-111.5)	Female	20	15.5	129.3	(78.9-199.6)
Female	48	60.4	79.5	(58.6-105.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	14	11.2	125.2	(68.4-210.0)
Male	7	9.4	74.6	(29.9-153.8)	Female	14	14.3	97.7	(53.4-164.0)
Female	5	3.2	155.5	(50.1-362.9)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	118	133.2	88.6	(73.3-106.1)
Male	5	3.2	156.7	(50.5-365.7)	<u>Stomach</u>				
Female	4	2.8	nc	(nc-nc)	Male	7	8.7	80.1	(32.1-165.1)
<u>Kidney & Renal Pelvis</u>					Female	5	6.7	74.3	(24.0-173.5)
Male	16	16.8	95.1	(54.3-154.4)	<u>Testis</u>				
Female	14	12.3	113.6	(62.1-190.7)	Male	6	5.9	102.2	(37.3-222.4)
<u>Larynx</u>					<u>Thyroid</u>				
Male	6	5.8	104.3	(38.1-227.0)	Male	5	5.7	88.4	(28.5-206.2)
Female	2	1.8	nc	(nc-nc)	Female	20	19.5	102.4	(62.5-158.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	8	12.1	66.1	(28.5-130.3)	Female	29	31.8	91.1	(61.0-130.8)
Female	10	11.2	89.5	(42.9-164.6)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	436	485.6	89.8	(81.5-98.6)
Male	6	8.1	74.3	(27.1-161.8)	Female	490	532.8	92.0	(84.0-100.5)
Female	1	3.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	65	69.3	93.9	(72.4-119.6)					
Female	72	77.2	93.2	(72.9-117.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wayland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	16.4	128.0	(79.2-195.7)	Male	13	10.0	129.5	(68.9-221.4)
Female	3	5.5	nc	(nc-nc)	Female	13	7.7	168.1	(89.4-287.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.0	nc	(nc-nc)	Male	4	2.6	nc	(nc-nc)
Female	4	2.4	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	13	8.6	151.2	(80.4-258.6)
Female	80	58.2	137.5	(109.1-171.2)	Female	7	7.2	96.9	(38.8-199.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.4	nc	(nc-nc)	Male	6	6.4	93.7	(34.2-203.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	22	23.1	95.4	(59.7-144.4)	Female	13	5.9	218.7	(116.4-374.1)
Female	22	19.9	110.4	(69.2-167.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	5.0	nc	(nc-nc)
Male	2	4.4	nc	(nc-nc)	Female	2	4.8	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	60	63.5	94.5	(72.1-121.7)
Male	2	1.1	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.8	nc	(nc-nc)	Male	2	3.7	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	2.1	nc	(nc-nc)
Male	3	7.8	nc	(nc-nc)	<u>Testis</u>				
Female	3	4.6	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	2.7	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	15	7.6	198.6	(111.1-327.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	5.3	nc	(nc-nc)	Female	15	13.2	113.9	(63.7-187.9)
Female	7	3.9	181.6	(72.8-374.2)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	200	219.0	91.3	(79.1-104.9)
Male	2	3.9	nc	(nc-nc)	Female	225	196.0	114.8	(100.3-130.8)
Female	1	1.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	22	30.8	71.4	(44.7-108.1)					
Female	24	27.3	87.9	(56.3-130.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Webster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	20.4	103.0	(63.8-157.5)	Male	10	12.2	82.2	(39.4-151.2)
Female	10	8.2	122.4	(58.6-225.2)	Female	2	10.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.6	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
Female	2	3.2	nc	(nc-nc)	Female	3	2.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	8	10.5	76.0	(32.7-149.8)
Female	68	71.8	94.8	(73.6-120.1)	Female	13	10.4	125.4	(66.7-214.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	3.0	203.2	(74.2-442.4)	Male	6	7.3	81.9	(29.9-178.2)
<u>Colon / Rectum</u>					Female	4	3.7	nc	(nc-nc)
Male	30	28.2	106.4	(71.8-151.9)	<u>Ovary</u>				
Female	32	30.4	105.4	(72.1-148.8)	Female	5	7.7	65.0	(21.0-151.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	5.1	136.0	(54.5-280.2)	Male	10	6.1	164.4	(78.7-302.4)
Female	3	1.6	nc	(nc-nc)	Female	6	7.2	83.9	(30.6-182.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.6	nc	(nc-nc)	Male	64	72.7	88.0	(67.7-112.3)
Female	1	1.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	4.7	nc	(nc-nc)
Male	8	9.2	86.9	(37.4-171.2)	Female	2	3.4	nc	(nc-nc)
Female	7	6.1	115.0	(46.1-237.1)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.6	nc	(nc-nc)
Male	3	3.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	0.9	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
<u>Leukemia</u>					Female	2	9.1	nc	(nc-nc)
Male	13	6.6	197.8	(105.2-338.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	5.7	123.4	(49.5-254.4)	Female	16	15.8	101.1	(57.7-164.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	4.5	nc	(nc-nc)	Male	256	262.4	97.6	(86.0-110.3)
Female	2	1.7	nc	(nc-nc)	Female	254	263.8	96.3	(84.8-108.9)
<u>Lung and Bronchus</u>									
Male	35	37.1	94.3	(65.7-131.1)					
Female	34	37.8	89.9	(62.2-125.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wellesley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	29.6	64.3	(38.7-100.4)	Male	38	18.0	211.3	(149.5-290.0)
Female	9	11.3	79.8	(36.4-151.5)	Female	17	15.4	110.6	(64.4-177.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	5.4	nc	(nc-nc)	Male	5	4.6	107.8	(34.7-251.5)
Female	1	5.0	nc	(nc-nc)	Female	2	3.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.0	nc	(nc-nc)	Male	12	15.5	77.5	(40.0-135.5)
Female	117	109.4	106.9	(88.4-128.1)	Female	11	14.7	74.9	(37.4-134.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	4.6	nc	(nc-nc)	Male	14	11.3	123.5	(67.4-207.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	31	41.6	74.6	(50.7-105.9)	Female	11	11.6	95.0	(47.4-170.0)
Female	38	41.2	92.1	(65.2-126.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	11	9.0	122.5	(61.1-219.2)
Male	4	7.7	nc	(nc-nc)	Female	9	9.8	92.0	(42.0-174.7)
Female	4	2.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	140	111.8	125.2	(105.4-147.8)
Male	5	2.1	238.0	(76.7-555.4)	<u>Stomach</u>				
Female	1	2.3	nc	(nc-nc)	Male	4	6.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	3	4.5	nc	(nc-nc)
Male	16	13.9	115.1	(65.7-186.9)	<u>Testis</u>				
Female	6	8.9	67.5	(24.6-146.9)	Male	3	3.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	4.8	nc	(nc-nc)	Male	5	4.4	113.8	(36.7-265.6)
Female	1	1.3	nc	(nc-nc)	Female	17	14.8	115.2	(67.0-184.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	16	9.6	166.1	(94.9-269.7)	Female	16	24.5	65.4	(37.3-106.2)
Female	4	8.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	378	391.1	96.7	(87.2-106.9)
Male	6	6.9	86.7	(31.6-188.6)	Female	334	385.7	86.6	(77.6-96.4)
Female	3	2.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	19	54.8	34.6	(20.8-54.1)					
Female	23	53.9	42.7	(27.0-64.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wellfleet

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	5.0	221.2	(110.3-395.9)	Male	1	2.7	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	7	2.0	345.5	(138.4-712.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.7	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	16	15.3	104.3	(59.6-169.4)	Female	2	2.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.6	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	5	6.7	74.4	(24.0-173.5)	Female	1	1.6	nc	(nc-nc)
Female	3	5.9	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	1	1.2	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	0	0.3	nc	(nc-nc)	Female	33	17.4	189.2	(130.2-265.7)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	0	2.1	nc	(nc-nc)	Female	3	1.1	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	1	0.7	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	2	1.5	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	1	1.0	nc	(nc-nc)	Male	6	3.5	171.2	(62.5-372.6)
Female	2	0.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	5	9.0	55.5	(17.9-129.6)	Female	74	61.7	120.0	(94.2-150.7)
Female	8	8.1	99.0	(42.6-195.1)	Female	60	54.2	110.7	(84.5-142.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wendell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.8	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	5	3.4	148.7	(47.9-347.1)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	2	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	1.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.3	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female				
<u>Hodgkin Lymphoma</u>					Female				
Male	0	0.1	nc	(nc-nc)	Male	2	3.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	0	0.5	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female				
<u>Larynx</u>					Female				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Testis</u>				
<u>Leukemia</u>					Male				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	0	0.3	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Lung and Bronchus</u>					Female				
Male	0	1.5	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	<u>All Sites / Types</u>				
					Male				
					Male				
					Female				
					Female				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wenham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	5.1	nc	(nc-nc)	Male	5	3.0	166.9	(53.8-389.4)
Female	2	1.8	nc	(nc-nc)	Female	9	2.4	377.3	(172.2-716.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	0.9	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
Female	15	16.7	89.6	(50.1-147.7)	Female	2	2.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.7	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	5	7.0	71.2	(23.0-166.2)	Female	1	1.8	nc	(nc-nc)
Female	14	6.4	219.6	(120.0-368.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	1.5	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	18	18.3	98.5	(58.4-155.7)
Male	2	0.4	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.4	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	0.7	nc	(nc-nc)
Male	1	2.3	nc	(nc-nc)	<u>Testis</u>				
Female	3	1.4	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	0.8	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.7	nc	(nc-nc)	Female	5	3.7	134.8	(43.4-314.5)
Female	0	1.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	65	65.7	98.9	(76.4-126.1)
Male	1	1.1	nc	(nc-nc)	Female	70	59.9	116.9	(91.1-147.7)
Female	1	0.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	13	9.4	137.9	(73.3-235.8)					
Female	8	8.6	93.0	(40.0-183.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Boylston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	9.0	66.5	(24.3-144.7)	Male	3	5.8	nc	(nc-nc)
Female	1	3.0	nc	(nc-nc)	Female	5	3.8	130.0	(41.9-303.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.8	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	6	5.0	120.8	(44.1-262.9)
Female	31	28.1	110.3	(74.9-156.6)	Female	5	3.8	130.1	(41.9-303.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	1.1	nc	(nc-nc)	Male	1	3.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	8	12.7	63.0	(27.1-124.1)	Female	5	2.9	169.7	(54.7-396.0)
Female	4	11.0	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	2.7	nc	(nc-nc)
Male	3	2.3	nc	(nc-nc)	Female	2	2.6	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	24	32.6	73.7	(47.2-109.7)
Male	1	0.9	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.4	nc	(nc-nc)	Male	0	2.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.2	nc	(nc-nc)
Male	5	4.3	117.1	(37.7-273.3)	<u>Testis</u>				
Female	2	2.3	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.4	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	3.5	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	3.0	nc	(nc-nc)	Female	8	6.2	129.1	(55.6-254.4)
Female	5	2.1	243.1	(78.3-567.3)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	92	119.8	76.8	(61.9-94.2)
Male	1	2.1	nc	(nc-nc)	Female	96	99.8	96.2	(77.9-117.4)
Female	0	0.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	14	16.5	84.6	(46.2-142.0)					
Female	13	14.3	90.9	(48.4-155.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	9.3	86.1	(37.1-169.7)	Male	6	5.4	110.5	(40.4-240.5)
Female	7	3.6	194.8	(78.0-401.3)	Female	4	4.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.6	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	5	4.7	106.5	(34.3-248.4)
Female	27	32.0	84.3	(55.5-122.6)	Female	5	4.5	110.1	(35.5-257.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.2	nc	(nc-nc)	Male	4	3.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	10	12.8	78.3	(37.5-143.9)	Female	1	3.4	nc	(nc-nc)
Female	12	13.2	91.1	(47.0-159.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	2.8	180.2	(58.1-420.5)
Male	4	2.3	nc	(nc-nc)	Female	2	3.1	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	36	33.8	106.6	(74.6-147.6)
Male	2	0.7	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.5	nc	(nc-nc)	Male	3	2.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.5	nc	(nc-nc)
Male	4	4.1	nc	(nc-nc)	<u>Testis</u>				
Female	2	2.7	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	1.4	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	4	3.8	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	2.9	nc	(nc-nc)	Female	7	7.2	97.2	(38.9-200.2)
Female	1	2.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	120	119.3	100.6	(83.4-120.3)
Male	2	2.0	nc	(nc-nc)	Female	102	116.2	87.8	(71.6-106.6)
Female	0	0.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	19	17.0	111.7	(67.2-174.5)					
Female	19	17.0	112.0	(67.4-174.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	5.2	nc	(nc-nc)	Male	1	3.0	nc	(nc-nc)
Female	0	2.6	nc	(nc-nc)	Female	0	2.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.8	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.2	nc	(nc-nc)	Male	5	2.6	191.0	(61.6-445.8)
Female	11	20.6	53.5	(26.7-95.7)	Female	0	3.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.8	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	6	7.1	84.1	(30.7-183.1)	Female	3	2.3	nc	(nc-nc)
Female	11	10.1	108.9	(54.3-194.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	1.5	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	Female	5	2.3	215.1	(69.3-501.9)
Female	0	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	20	17.8	112.4	(68.6-173.6)
Male	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.2	nc	(nc-nc)
Male	2	2.2	nc	(nc-nc)	<u>Testis</u>				
Female	3	1.7	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.8	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	3	2.2	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.6	nc	(nc-nc)	Female	4	4.4	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	58	64.8	89.6	(68.0-115.8)
Male	0	1.1	nc	(nc-nc)	Female	48	78.6	61.1	(45.0-81.0)
Female	0	0.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	9	9.0	100.0	(45.6-189.9)					
Female	3	11.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Newbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	3.9	nc	(nc-nc)	Male	1	2.8	nc	(nc-nc)
Female	3	1.3	nc	(nc-nc)	Female	8	2.2	366.1	(157.6-721.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.9	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	2.3	nc	(nc-nc)
Female	13	15.8	82.2	(43.7-140.5)	Female	2	1.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.7	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	6	5.9	101.3	(37.0-220.4)	Female	3	1.6	nc	(nc-nc)
Female	8	4.7	171.3	(73.7-337.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	1	1.1	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	24	16.7	143.9	(92.2-214.1)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	1	2.2	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.7	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	1.4	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	3	2.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.1	nc	(nc-nc)	Female	1	3.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	5	7.5	66.8	(21.5-155.8)	Male	51	57.3	89.0	(66.3-117.0)
Female	6	6.4	93.4	(34.1-203.2)	Female	53	50.4	105.1	(78.7-137.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Springfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	35	34.1	102.8	(71.6-142.9)	Male	16	20.5	78.0	(44.6-126.8)
Female	10	12.6	79.3	(38.0-145.8)	Female	13	16.4	79.1	(42.1-135.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	6.1	148.5	(67.8-282.0)	Male	3	5.3	nc	(nc-nc)
Female	2	5.1	nc	(nc-nc)	Female	2	4.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.1	nc	(nc-nc)	Male	14	17.6	79.4	(43.4-133.3)
Female	116	117.2	99.0	(81.8-118.7)	Female	15	16.2	92.8	(51.9-153.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	4.8	nc	(nc-nc)	Male	13	12.4	105.0	(55.8-179.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	41	47.1	87.0	(62.4-118.0)	Female	14	12.4	113.1	(61.8-189.8)
Female	41	45.8	89.6	(64.3-121.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	11	10.2	107.9	(53.8-193.1)
Male	12	8.7	138.3	(71.4-241.6)	Female	11	10.9	100.9	(50.3-180.6)
Female	2	2.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	133	125.2	106.2	(89.0-125.9)
Male	2	2.7	nc	(nc-nc)	<u>Stomach</u>				
Female	3	2.1	nc	(nc-nc)	Male	10	7.8	128.0	(61.3-235.5)
<u>Kidney & Renal Pelvis</u>					Female	6	5.0	120.0	(43.8-261.1)
Male	24	15.5	154.4	(98.9-229.7)	<u>Testis</u>				
Female	8	9.8	81.8	(35.2-161.1)	Male	4	4.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	5.4	nc	(nc-nc)	Male	4	5.0	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	12	15.3	78.5	(40.5-137.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	12	10.9	109.6	(56.6-191.5)	Female	19	26.3	72.3	(43.5-112.8)
Female	5	8.7	57.7	(18.6-134.7)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	435	443.7	98.0	(89.0-107.7)
Male	2	7.6	nc	(nc-nc)	Female	380	419.3	90.6	(81.7-100.2)
Female	3	2.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	62	62.7	98.8	(75.7-126.7)					
Female	53	60.5	87.6	(65.6-114.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Stockbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.2	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	11	7.1	154.7	(77.1-276.8)	Female	0	0.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	3.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.6	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	9	7.8	114.8	(52.4-217.9)
Female	1	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	1	1.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	0.7	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.5	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	2	4.0	nc	(nc-nc)	Male	24	28.1	85.4	(54.7-127.1)
Female	4	3.5	nc	(nc-nc)	Female	22	24.2	91.0	(57.0-137.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Tisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.8	nc	(nc-nc)	Male	4	1.9	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	4	1.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.6	nc	(nc-nc)	Male	2	0.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	10	10.7	93.9	(44.9-172.6)	Female	0	1.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	4.1	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
Female	7	3.2	215.7	(86.4-444.4)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	0.8	nc	(nc-nc)	Male	19	11.0	172.5	(103.8-269.4)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	1	0.2	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.4	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.5	nc	(nc-nc)	Male	44	38.7	113.8	(82.7-152.8)
Female	0	0.1	nc	(nc-nc)	Female	30	34.3	87.3	(58.9-124.7)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	0.9	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	1	0.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.7	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	1	5.2	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	4	4.5	nc	(nc-nc)	<u>All Sites / Types</u>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	16.9	88.9	(49.7-146.7)	Male	11	11.4	96.2	(47.9-172.1)
Female	4	6.6	nc	(nc-nc)	Female	14	9.8	143.0	(78.1-240.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.6	nc	(nc-nc)	Male	3	2.7	nc	(nc-nc)
Female	3	3.0	nc	(nc-nc)	Female	4	2.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	15	9.7	154.3	(86.3-254.4)
Female	63	66.4	94.9	(72.9-121.4)	Female	8	8.8	90.9	(39.1-179.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	3.1	nc	(nc-nc)	Male	5	7.0	71.3	(23.0-166.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	20	24.5	81.8	(49.9-126.3)	Female	9	6.9	130.2	(59.4-247.2)
Female	18	25.3	71.3	(42.2-112.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	9	5.2	174.4	(79.6-331.0)
Male	3	4.5	nc	(nc-nc)	Female	1	5.8	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	64	62.4	102.5	(78.9-130.9)
Male	1	1.7	nc	(nc-nc)	<u>Stomach</u>				
Female	2	1.3	nc	(nc-nc)	Male	6	4.0	149.7	(54.6-325.7)
<u>Kidney & Renal Pelvis</u>					Female	0	2.8	nc	(nc-nc)
Male	14	8.4	166.5	(91.0-279.4)	<u>Testis</u>				
Female	1	5.2	nc	(nc-nc)	Male	1	3.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	2.8	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	8	9.8	81.6	(35.1-160.8)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	9	6.0	149.9	(68.4-284.6)	Female	11	14.1	77.9	(38.8-139.4)
Female	2	5.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	221	230.2	96.0	(83.8-109.6)
Male	3	4.2	nc	(nc-nc)	Female	193	232.4	83.0	(71.7-95.6)
Female	2	1.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	19	30.7	61.8	(37.2-96.5)					
Female	25	30.5	82.0	(53.1-121.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	41	42.6	96.2	(69.0-130.5)	Male	23	26.5	86.9	(55.1-130.4)
Female	15	16.2	92.3	(51.6-152.3)	Female	17	22.0	77.2	(44.9-123.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	8.1	74.5	(27.2-162.2)	Male	5	6.7	75.1	(24.2-175.2)
Female	5	6.9	72.1	(23.2-168.2)	Female	2	5.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.3	nc	(nc-nc)	Male	16	22.8	70.1	(40.0-113.8)
Female	163	153.7	106.0	(90.4-123.6)	Female	31	21.1	147.2	(100.0-209.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	10	6.6	152.0	(72.8-279.5)	Male	13	16.2	80.3	(42.7-137.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	66	59.8	110.3	(85.3-140.4)	Female	18	16.3	110.4	(65.4-174.5)
Female	49	59.6	82.3	(60.8-108.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	13	12.9	101.1	(53.8-173.0)
Male	15	11.0	136.3	(76.2-224.8)	Female	12	14.1	85.1	(43.9-148.7)
Female	4	3.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	142	156.1	91.0	(76.6-107.2)
Male	3	3.8	nc	(nc-nc)	<u>Stomach</u>				
Female	3	3.1	nc	(nc-nc)	Male	14	9.9	142.0	(77.6-238.3)
<u>Kidney & Renal Pelvis</u>					Female	8	6.5	122.2	(52.6-240.9)
Male	24	19.9	120.8	(77.4-179.8)	<u>Testis</u>				
Female	7	12.7	55.3	(22.2-113.9)	Male	8	6.3	127.3	(54.8-250.9)
<u>Larynx</u>					<u>Thyroid</u>				
Male	5	6.8	73.9	(23.8-172.4)	Male	1	6.7	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	Female	19	21.1	90.2	(54.3-140.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	9	14.2	63.2	(28.8-120.0)	Female	39	34.1	114.4	(81.4-156.4)
Female	3	11.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	535	562.3	95.1	(87.2-103.6)
Male	5	9.8	50.9	(16.4-118.7)	Female	547	548.5	99.7	(91.5-108.4)
Female	4	3.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	94	78.1	120.3	(97.2-147.2)					
Female	79	77.2	102.4	(81.1-127.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	15.5	110.0	(64.0-176.1)	Male	16	11.8	135.2	(77.2-219.6)
Female	6	5.5	108.7	(39.7-236.7)	Female	12	10.0	119.8	(61.9-209.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	4.0	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
Female	4	3.1	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	6	9.9	60.7	(22.2-132.2)
Female	66	69.1	95.5	(73.8-121.5)	Female	9	7.9	114.4	(52.2-217.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	3.5	nc	(nc-nc)	Male	3	7.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	29	23.8	122.0	(81.7-175.2)	Female	13	6.9	189.3	(100.7-323.7)
Female	21	20.4	103.2	(63.8-157.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	5.0	nc	(nc-nc)
Male	2	4.6	nc	(nc-nc)	Female	4	4.7	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	61	66.8	91.4	(69.9-117.4)
Male	0	1.8	nc	(nc-nc)	<u>Stomach</u>				
Female	2	1.3	nc	(nc-nc)	Male	3	3.7	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	4	2.2	nc	(nc-nc)
Male	11	9.0	122.1	(60.9-218.5)	<u>Testis</u>				
Female	3	5.0	nc	(nc-nc)	Male	4	3.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	2.9	nc	(nc-nc)	Male	7	3.6	196.2	(78.6-404.2)
Female	0	0.7	nc	(nc-nc)	Female	14	11.3	124.3	(67.9-208.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	6.0	117.6	(47.1-242.3)	Female	12	15.0	80.2	(41.4-140.1)
Female	3	4.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	229	233.8	98.0	(85.7-111.5)
Male	3	4.5	nc	(nc-nc)	Female	221	222.0	99.6	(86.9-113.6)
Female	2	1.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	28	30.1	93.0	(61.8-134.4)					
Female	28	27.4	102.3	(67.9-147.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westhampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.5	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	0.9	nc	(nc-nc)
Female	5	6.0	82.9	(26.7-193.4)	Female	0	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	2.3	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.1	nc	(nc-nc)	Male	7	6.5	107.6	(43.1-221.8)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	0	0.8	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	0.5	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.4	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	3	3.0	nc	(nc-nc)	Male	20	22.1	90.3	(55.1-139.5)
Female	0	2.4	nc	(nc-nc)	Female	12	19.0	63.0	(32.5-110.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westminster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	7.2	111.7	(48.1-220.2)	Male	3	4.9	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	Female	5	3.8	132.1	(42.6-308.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.5	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	4.1	nc	(nc-nc)
Female	24	26.8	89.7	(57.4-133.4)	Female	3	3.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.2	nc	(nc-nc)	Male	3	3.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	18	10.6	170.5	(101.0-269.5)	Female	1	2.7	nc	(nc-nc)
Female	5	8.6	58.4	(18.8-136.3)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	1	2.0	nc	(nc-nc)	Male	28	28.3	99.0	(65.8-143.1)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.7	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	3.7	nc	(nc-nc)	Female	9	5.8	154.1	(70.3-292.5)
Female	3	2.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.2	nc	(nc-nc)	Female	9	5.8	154.1	(70.3-292.5)
Female	0	0.3	nc	(nc-nc)	Male	98	100.3	97.7	(79.3-119.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	2.5	nc	(nc-nc)	Female	94	88.2	106.6	(86.1-130.4)
Female	1	1.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.9	nc	(nc-nc)	Male	98	100.3	97.7	(79.3-119.1)
Female	0	0.5	nc	(nc-nc)	Female	94	88.2	106.6	(86.1-130.4)
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	9	13.5	66.8	(30.5-126.8)	Male	98	100.3	97.7	(79.3-119.1)
Female	13	11.6	112.1	(59.6-191.7)	Female	94	88.2	106.6	(86.1-130.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Weston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	16.8	41.6	(16.7-85.7)	Male	15	9.7	154.8	(86.6-255.4)
Female	6	5.4	111.3	(40.6-242.3)	Female	9	6.9	129.6	(59.1-246.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.8	nc	(nc-nc)	Male	3	2.6	nc	(nc-nc)
Female	3	2.2	nc	(nc-nc)	Female	0	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	6	8.4	71.5	(26.1-155.6)
Female	52	51.5	101.0	(75.4-132.5)	Female	9	6.9	130.1	(59.4-247.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.0	nc	(nc-nc)	Male	1	6.0	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	15	23.2	64.5	(36.1-106.4)	Female	3	5.4	nc	(nc-nc)
Female	15	20.0	75.1	(42.0-123.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	5.0	nc	(nc-nc)
Male	1	4.3	nc	(nc-nc)	Female	5	4.7	106.3	(34.3-248.1)
Female	2	1.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	75	61.3	122.3	(96.2-153.3)
Male	3	1.0	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.8	nc	(nc-nc)	Male	4	3.9	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	3	2.2	nc	(nc-nc)
Male	10	7.5	133.7	(64.0-245.9)	<u>Testis</u>				
Female	5	4.2	120.2	(38.7-280.4)	Male	2	1.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	2.6	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	14	6.4	219.6	(120.0-368.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	5.2	nc	(nc-nc)	Female	10	11.5	86.6	(41.5-159.3)
Female	3	3.8	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	190	214.8	88.5	(76.3-102.0)
Male	1	3.7	nc	(nc-nc)	Female	179	181.1	98.8	(84.9-114.4)
Female	1	1.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	16	30.5	52.5	(30.0-85.2)					
Female	18	25.3	71.1	(42.1-112.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	26	18.8	138.7	(90.6-203.2)	Male	10	11.7	85.4	(40.9-157.0)
Female	7	6.3	111.5	(44.6-229.6)	Female	6	8.8	68.0	(24.8-148.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.4	nc	(nc-nc)	Male	4	3.0	nc	(nc-nc)
Female	2	2.7	nc	(nc-nc)	Female	4	2.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	10	10.0	100.3	(48.0-184.6)
Female	79	64.6	122.2	(96.8-152.3)	Female	5	8.2	60.8	(19.6-141.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.7	nc	(nc-nc)	Male	7	7.5	93.0	(37.3-191.7)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	19	26.6	71.5	(43.0-111.7)	Female	7	6.7	105.0	(42.1-216.3)
Female	28	22.5	124.6	(82.8-180.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	5.8	nc	(nc-nc)
Male	3	5.1	nc	(nc-nc)	Female	9	5.4	167.6	(76.5-318.1)
Female	1	1.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	64	74.2	86.3	(66.4-110.2)
Male	3	1.4	nc	(nc-nc)	<u>Stomach</u>				
Female	2	1.1	nc	(nc-nc)	Male	5	4.3	116.6	(37.6-272.1)
<u>Kidney & Renal Pelvis</u>					Female	2	2.4	nc	(nc-nc)
Male	7	9.0	77.4	(31.0-159.4)	<u>Testis</u>				
Female	5	5.2	97.0	(31.3-226.3)	Male	3	2.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	3.2	nc	(nc-nc)	Male	4	2.9	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	14	8.6	162.8	(88.9-273.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	6.0	100.1	(36.6-218.0)	Female	22	14.9	148.1	(92.8-224.3)
Female	5	4.3	117.1	(37.7-273.3)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	245	253.8	96.5	(84.8-109.4)
Male	3	4.5	nc	(nc-nc)	Female	257	220.5	116.5	(102.7-131.7)
Female	2	1.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	41	35.3	116.1	(83.3-157.4)					
Female	32	31.1	103.1	(70.5-145.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westwood

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	20.8	72.1	(40.3-118.9)	Male	11	11.7	94.4	(47.0-168.8)
Female	6	7.6	78.9	(28.8-171.8)	Female	19	9.0	211.8	(127.5-330.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	3.3	239.6	(103.2-472.2)	Male	1	3.1	nc	(nc-nc)
Female	2	2.9	nc	(nc-nc)	Female	6	2.4	248.9	(90.9-541.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	14	10.2	137.6	(75.1-230.8)
Female	69	66.5	103.8	(80.8-131.4)	Female	13	9.5	136.3	(72.5-233.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.6	nc	(nc-nc)	Male	7	6.9	101.5	(40.7-209.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	24	28.2	85.1	(54.5-126.6)	Female	7	7.1	98.9	(39.6-203.9)
Female	30	28.3	106.0	(71.5-151.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	6.1	81.9	(26.4-191.1)
Male	2	5.0	nc	(nc-nc)	Female	12	6.7	179.9	(92.8-314.3)
Female	0	1.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	71	71.0	100.0	(78.1-126.1)
Male	0	1.2	nc	(nc-nc)	<u>Stomach</u>				
Female	2	1.0	nc	(nc-nc)	Male	2	4.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	3	3.2	nc	(nc-nc)
Male	8	8.8	90.5	(39.0-178.3)	<u>Testis</u>				
Female	3	5.6	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	3.1	nc	(nc-nc)	Male	4	2.6	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	6	7.7	77.5	(28.3-168.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	6.5	93.0	(34.0-202.4)	Female	11	14.6	75.2	(37.5-134.5)
Female	4	5.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	229	257.1	89.1	(77.9-101.4)
Male	2	4.3	nc	(nc-nc)	Female	256	242.8	105.4	(92.9-119.2)
Female	2	1.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	26	37.0	70.3	(45.9-103.0)					
Female	31	35.1	88.4	(60.0-125.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Weymouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	76	62.0	122.6	(96.6-153.4)	Male	44	38.2	115.3	(83.8-154.8)
Female	21	25.1	83.5	(51.7-127.7)	Female	39	33.2	117.5	(83.6-160.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	11.5	87.3	(41.8-160.6)	Male	10	9.7	103.3	(49.4-189.9)
Female	8	10.3	77.9	(33.5-153.5)	Female	3	8.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	2.0	nc	(nc-nc)	Male	37	32.6	113.4	(79.8-156.3)
Female	227	238.2	95.3	(83.3-108.6)	Female	24	32.2	74.6	(47.8-110.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	8	10.0	80.0	(34.4-157.6)	Male	26	23.4	111.2	(72.6-162.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	82	86.6	94.7	(75.3-117.6)	Female	30	24.9	120.2	(81.1-171.7)
Female	86	90.7	94.9	(75.9-117.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	18	18.7	96.0	(56.9-151.8)
Male	23	16.2	142.3	(90.2-213.5)	Female	18	21.6	83.2	(49.3-131.5)
Female	3	4.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	212	235.0	90.2	(78.5-103.2)
Male	3	4.9	nc	(nc-nc)	<u>Stomach</u>				
Female	2	4.1	nc	(nc-nc)	Male	10	14.2	70.6	(33.8-129.8)
<u>Kidney & Renal Pelvis</u>					Female	12	9.9	121.6	(62.8-212.5)
Male	37	29.2	126.9	(89.3-174.9)	<u>Testis</u>				
Female	27	19.7	137.0	(90.3-199.4)	Male	10	8.3	120.2	(57.5-221.0)
<u>Larynx</u>					<u>Thyroid</u>				
Male	7	10.0	69.7	(27.9-143.7)	Male	7	9.6	72.8	(29.2-149.9)
Female	2	2.9	nc	(nc-nc)	Female	39	31.3	124.4	(88.5-170.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	16	20.1	79.5	(45.4-129.1)	Female	45	53.4	84.3	(61.5-112.8)
Female	17	17.2	98.9	(57.6-158.4)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	843	823.3	102.4	(95.6-109.5)
Male	10	14.3	70.1	(33.6-129.0)	Female	841	843.2	99.7	(93.1-106.7)
Female	6	5.4	112.0	(40.9-243.7)					
<u>Lung and Bronchus</u>									
Male	129	115.9	111.3	(92.9-132.2)					
Female	159	121.2	131.1	(111.5-153.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Whately

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.9	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.4	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	5	6.5	77.4	(24.9-180.7)	Female	1	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	2.8	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	3	2.2	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.6	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	5	7.2	69.4	(22.4-162.0)
Male	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	0.2	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	<u>Testis</u>				
Female	1	0.5	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.6	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	23	25.8	89.1	(56.5-133.7)
Male	0	0.5	nc	(nc-nc)	Female	16	21.5	74.4	(42.5-120.8)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	4	3.5	nc	(nc-nc)					
Female	1	2.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Whitman

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	12.1	115.6	(63.2-194.0)	Male	6	8.4	71.7	(26.2-156.1)
Female	3	4.5	nc	(nc-nc)	Female	6	7.2	83.3	(30.4-181.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	2.7	187.4	(60.4-437.4)	Male	2	2.0	nc	(nc-nc)
Female	6	2.2	269.0	(98.2-585.5)	Female	1	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	9	7.1	127.1	(58.0-241.4)
Female	48	49.2	97.6	(72.0-129.5)	Female	6	6.1	97.9	(35.8-213.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	2.4	nc	(nc-nc)	Male	7	5.3	131.8	(52.8-271.7)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	14	17.7	78.9	(43.1-132.5)	Female	2	5.1	nc	(nc-nc)
Female	18	16.3	110.8	(65.6-175.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	3.8	132.0	(42.5-307.9)
Male	7	3.4	207.4	(83.1-427.4)	Female	6	3.9	155.7	(56.9-338.9)
Female	2	0.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	31	49.2	63.0	(42.8-89.4)
Male	2	1.3	nc	(nc-nc)	<u>Stomach</u>				
Female	3	1.1	nc	(nc-nc)	Male	1	2.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	1.7	nc	(nc-nc)
Male	9	6.3	142.4	(65.0-270.4)	<u>Testis</u>				
Female	3	3.8	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	2.1	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	7	7.6	91.9	(36.8-189.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	4.3	nc	(nc-nc)	Female	6	10.9	54.8	(20.0-119.4)
Female	5	3.4	148.2	(47.8-345.9)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	165	172.4	95.7	(81.6-111.5)
Male	1	3.1	nc	(nc-nc)	Female	168	166.4	101.0	(86.3-117.5)
Female	2	1.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	26	23.1	112.8	(73.7-165.3)					
Female	26	22.3	116.5	(76.1-170.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wilbraham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	18.8	69.1	(36.7-118.1)	Male	13	11.2	115.9	(61.7-198.3)
Female	10	6.8	147.1	(70.4-270.6)	Female	9	8.7	103.7	(47.3-196.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.3	nc	(nc-nc)	Male	3	2.9	nc	(nc-nc)
Female	3	2.7	nc	(nc-nc)	Female	3	2.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	15	9.7	155.3	(86.9-256.2)
Female	90	64.7	139.2	(111.9-171.1)	Female	18	8.7	207.5	(122.9-327.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.6	nc	(nc-nc)	Male	2	7.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	18	26.3	68.5	(40.6-108.3)	Female	11	6.8	162.9	(81.2-291.4)
Female	36	24.9	144.6	(101.3-200.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	5.7	nc	(nc-nc)
Male	2	4.9	nc	(nc-nc)	Female	6	5.9	101.6	(37.1-221.1)
Female	2	1.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	94	70.9	132.6	(107.2-162.3)
Male	0	1.2	nc	(nc-nc)	<u>Stomach</u>				
Female	3	1.0	nc	(nc-nc)	Male	3	4.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	3	2.7	nc	(nc-nc)
Male	6	8.7	68.9	(25.2-149.9)	<u>Testis</u>				
Female	3	5.3	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	3.0	nc	(nc-nc)	Male	4	2.7	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	9	7.9	113.3	(51.7-215.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	5.9	101.2	(37.0-220.3)	Female	15	14.5	103.5	(57.9-170.7)
Female	3	4.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	215	246.5	87.2	(75.9-99.7)
Male	2	4.3	nc	(nc-nc)	Female	263	227.3	115.7	(102.2-130.6)
Female	4	1.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	15	35.0	42.9	(24.0-70.8)					
Female	16	32.4	49.4	(28.2-80.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Williamsburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	3.1	222.9	(89.3-459.3)	Male	1	1.9	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.5	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	1.7	nc	(nc-nc)
Female	13	10.6	122.5	(65.2-209.5)	Female	2	1.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.5	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	7	4.5	156.8	(62.8-323.2)	Female	1	1.1	nc	(nc-nc)
Female	3	3.4	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	1.0	nc	(nc-nc)
Male	2	0.8	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	9	11.7	76.9	(35.1-146.0)
Male	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.2	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.4	nc	(nc-nc)
Male	0	1.5	nc	(nc-nc)	<u>Testis</u>				
Female	2	0.8	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.0	nc	(nc-nc)	Female	3	2.4	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	43	41.4	103.8	(75.1-139.9)
Male	1	0.7	nc	(nc-nc)	Female	36	35.1	102.6	(71.8-142.0)
Female	0	0.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	5	5.7	87.3	(28.1-203.7)					
Female	3	4.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Williamstown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	10.9	82.6	(37.7-156.7)	Male	9	5.9	151.5	(69.1-287.6)
Female	0	4.7	nc	(nc-nc)	Female	5	5.1	97.1	(31.3-226.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.7	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	8	5.3	151.7	(65.3-298.9)
Female	34	36.7	92.6	(64.1-129.4)	Female	8	5.8	138.4	(59.6-272.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.3	nc	(nc-nc)	Male	2	3.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	6	14.6	41.2	(15.0-89.7)	Female	2	4.1	nc	(nc-nc)
Female	14	17.7	79.1	(43.2-132.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	3.2	nc	(nc-nc)
Male	3	2.6	nc	(nc-nc)	Female	2	4.1	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	67	36.4	184.0	(142.6-233.7)
Male	1	0.9	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.7	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	2.0	nc	(nc-nc)
Male	2	4.4	nc	(nc-nc)	<u>Testis</u>				
Female	1	3.2	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	1.6	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	Female	2	4.1	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	3.4	206.1	(82.6-424.7)	Female	11	8.1	135.1	(67.3-241.7)
Female	6	3.1	191.8	(70.0-417.5)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	153	133.2	114.9	(97.4-134.6)
Male	0	2.2	nc	(nc-nc)	Female	126	141.9	88.8	(73.9-105.7)
Female	1	1.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	17	19.3	88.2	(51.4-141.3)					
Female	24	20.8	115.4	(73.9-171.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wilmington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	19.8	90.8	(53.8-143.6)	Male	16	13.4	119.4	(68.2-193.9)
Female	4	7.4	nc	(nc-nc)	Female	9	11.1	80.8	(36.9-153.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	4.3	nc	(nc-nc)	Male	3	3.2	nc	(nc-nc)
Female	5	3.5	143.1	(46.1-334.0)	Female	2	2.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	8	11.3	70.6	(30.4-139.0)
Female	91	77.6	117.3	(94.4-144.0)	Female	10	9.8	101.8	(48.7-187.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.6	nc	(nc-nc)	Male	8	8.5	94.5	(40.7-186.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	34	28.7	118.5	(82.0-165.5)	Female	10	8.0	125.3	(60.0-230.5)
Female	23	26.7	86.0	(54.5-129.1)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	4	5.5	nc	(nc-nc)	Male	86	80.0	107.5	(86.0-132.8)
Female	2	1.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	2	1.9	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
Female	3	1.5	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	13	10.2	127.4	(67.7-217.8)	Female	27	17.3	156.4	(103.1-227.6)
Female	7	6.1	114.6	(45.9-236.1)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	3.4	nc	(nc-nc)	Male	296	278.7	106.2	(94.4-119.0)
Female	1	0.9	nc	(nc-nc)	Female	298	265.3	112.3	(99.9-125.8)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	9	7.0	129.3	(59.0-245.5)	<u>All Sites / Types</u>				
Female	9	5.5	164.6	(75.1-312.4)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	5.0	nc	(nc-nc)	Male	296	278.7	106.2	(94.4-119.0)
Female	4	1.6	nc	(nc-nc)	Female	298	265.3	112.3	(99.9-125.8)
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	46	37.8	121.7	(89.1-162.3)	<u>All Sites / Types</u>				
Female	44	36.0	122.1	(88.7-163.9)	<u>All Sites / Types</u>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Winchendon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	8.7	91.4	(39.4-180.2)	Male	2	6.0	nc	(nc-nc)
Female	3	3.2	nc	(nc-nc)	Female	2	4.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.9	nc	(nc-nc)	Male	3	1.4	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	3	5.1	nc	(nc-nc)
Female	27	33.1	81.5	(53.7-118.5)	Female	2	4.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.6	nc	(nc-nc)	Male	5	3.7	133.8	(43.1-312.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	9	12.7	70.8	(32.3-134.5)	Female	8	3.4	233.2	(100.4-459.4)
Female	6	11.5	52.3	(19.1-113.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	3	2.4	nc	(nc-nc)	Female	1	2.7	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	0	0.9	nc	(nc-nc)	Female	32	34.9	91.8	(62.8-129.5)
Female	1	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	5	4.5	110.8	(35.7-258.6)	Female	3	2.0	nc	(nc-nc)
Female	4	2.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	1	1.5	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	3	3.1	nc	(nc-nc)	Female	2	5.1	nc	(nc-nc)
Female	2	2.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	3	2.2	nc	(nc-nc)	Male	8	7.3	109.3	(47.0-215.3)
Female	0	0.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	18	16.5	108.9	(64.5-172.1)	Female	116	122.8	94.4	(78.0-113.3)
Female	26	15.4	168.5	(110.0-246.9)	Female	109	114.1	95.6	(78.5-115.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Winchester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	32	27.8	115.0	(78.7-162.4)	Male	20	16.5	121.5	(74.2-187.7)
Female	5	10.9	45.7	(14.7-106.6)	Female	15	13.6	110.3	(61.7-182.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	12	4.8	249.3	(128.7-435.5)	Male	3	4.3	nc	(nc-nc)
Female	5	4.3	116.8	(37.6-272.6)	Female	5	3.5	143.7	(46.3-335.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	0.9	nc	(nc-nc)	Male	16	14.2	112.9	(64.5-183.4)
Female	117	99.8	117.3	(97.0-140.6)	Female	12	13.9	86.4	(44.6-150.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	4.0	nc	(nc-nc)	Male	7	10.1	69.2	(27.7-142.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	24	38.5	62.3	(39.9-92.7)	Female	11	10.5	104.3	(52.0-186.7)
Female	30	40.8	73.5	(49.6-105.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	8.4	59.9	(19.3-139.7)
Male	2	7.1	nc	(nc-nc)	Female	5	9.6	52.2	(16.8-121.8)
Female	2	2.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	101	102.3	98.7	(80.4-120.0)
Male	2	1.8	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.5	nc	(nc-nc)	Male	4	6.4	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	3	4.6	nc	(nc-nc)
Male	16	12.6	126.6	(72.3-205.6)	<u>Testis</u>				
Female	7	8.2	85.0	(34.0-175.1)	Male	3	2.8	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	5	4.4	114.0	(36.7-266.1)	Male	5	3.9	128.5	(41.4-299.8)
Female	0	1.2	nc	(nc-nc)	Female	15	12.2	123.4	(69.0-203.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	8	8.8	90.9	(39.1-179.0)	Female	27	22.2	121.9	(80.3-177.4)
Female	6	7.6	79.4	(29.0-172.8)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	328	359.8	91.2	(81.6-101.6)
Male	3	6.2	nc	(nc-nc)	Female	336	358.3	93.8	(84.0-104.4)
Female	2	2.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	35	51.0	68.6	(47.8-95.4)					
Female	36	50.7	71.0	(49.7-98.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Windsor

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.9	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	2	3.3	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	1.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	3	3.7	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.3	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	8	12.9	62.1	(26.7-122.3)
Male	0	0.3	nc	(nc-nc)	Female	7	10.8	64.6	(25.9-133.1)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	0	1.7	nc	(nc-nc)					
Female	0	1.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Winthrop

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	23	20.8	110.5	(70.0-165.8)	Male	19	12.7	149.3	(89.8-233.1)
Female	9	8.3	107.9	(49.2-204.8)	Female	13	11.0	118.4	(63.0-202.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	3.7	187.9	(75.3-387.2)	Male	1	3.2	nc	(nc-nc)
Female	1	3.4	nc	(nc-nc)	Female	3	2.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	9	10.9	82.5	(37.7-156.7)
Female	76	76.5	99.3	(78.2-124.3)	Female	16	10.7	150.2	(85.8-243.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.3	nc	(nc-nc)	Male	6	7.6	78.6	(28.7-171.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	28	29.0	96.6	(64.2-139.6)	Female	14	8.1	173.1	(94.6-290.5)
Female	37	30.6	120.8	(85.0-166.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	6.2	nc	(nc-nc)
Male	7	5.3	132.0	(52.9-271.9)	Female	7	7.2	96.6	(38.7-199.0)
Female	1	1.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	77	75.5	101.9	(80.4-127.4)
Male	0	1.6	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.4	nc	(nc-nc)	Male	2	4.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	3	3.4	nc	(nc-nc)
Male	19	9.6	198.5	(119.4-309.9)	<u>Testis</u>				
Female	8	6.4	125.3	(54.0-246.9)	Male	3	2.9	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	3.3	nc	(nc-nc)	Male	4	3.2	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	8	10.4	77.3	(33.3-152.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	8	6.7	119.6	(51.5-235.7)	Female	24	16.8	142.9	(91.5-212.6)
Female	4	5.8	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	294	271.1	108.5	(96.4-121.6)
Male	4	4.7	nc	(nc-nc)	Female	299	275.9	108.4	(96.4-121.4)
Female	1	1.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	47	38.1	123.5	(90.7-164.2)					
Female	50	39.3	127.3	(94.5-167.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Woburn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	42	43.6	96.4	(69.5-130.3)	Male	34	26.9	126.6	(87.6-176.9)
Female	19	16.5	115.0	(69.2-179.7)	Female	25	21.9	114.0	(73.7-168.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	8.0	nc	(nc-nc)	Male	9	6.8	133.0	(60.7-252.4)
Female	7	6.8	103.5	(41.5-213.2)	Female	6	5.2	116.0	(42.4-252.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.4	nc	(nc-nc)	Male	25	22.9	109.1	(70.6-161.1)
Female	169	155.4	108.7	(93.0-126.4)	Female	22	21.0	104.6	(65.6-158.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	6.6	nc	(nc-nc)	Male	18	16.1	111.7	(66.2-176.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	60	60.5	99.1	(75.6-127.6)	Female	10	16.3	61.5	(29.4-113.0)
Female	62	58.7	105.7	(81.0-135.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	21	13.1	160.3	(99.2-245.1)
Male	12	11.3	106.5	(55.0-186.0)	Female	18	14.1	127.7	(75.6-201.8)
Female	2	3.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	156	164.6	94.8	(80.5-110.9)
Male	2	3.6	nc	(nc-nc)	<u>Stomach</u>				
Female	4	2.8	nc	(nc-nc)	Male	10	9.9	100.7	(48.2-185.1)
<u>Kidney & Renal Pelvis</u>					Female	2	6.4	nc	(nc-nc)
Male	24	20.4	117.6	(75.3-175.0)	<u>Testis</u>				
Female	5	12.9	38.8	(12.5-90.4)	Male	3	6.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	8	7.0	114.1	(49.1-224.9)	Male	6	6.9	87.5	(32.0-190.5)
Female	1	2.0	nc	(nc-nc)	Female	25	20.9	119.4	(77.2-176.3)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	23	14.1	163.4	(103.6-245.2)	Female	30	35.0	85.7	(57.8-122.3)
Female	10	11.2	89.1	(42.6-163.8)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	595	577.7	103.0	(94.9-111.6)
Male	4	9.8	nc	(nc-nc)	Female	574	552.2	104.0	(95.6-112.8)
Female	3	3.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	90	81.7	110.1	(88.5-135.3)					
Female	101	80.3	125.8	(102.4-152.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Worcester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	159	172.9	91.9	(78.2-107.4)	Male	61	106.8	57.1	(43.7-73.4)
Female	61	70.1	87.1	(66.6-111.9)	Female	50	94.9	52.7	(39.1-69.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	21	33.1	63.4	(39.2-96.9)	Male	26	26.6	97.6	(63.8-143.1)
Female	33	30.0	109.8	(75.6-154.2)	Female	18	22.1	81.4	(48.2-128.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	5.4	nc	(nc-nc)	Male	85	92.3	92.0	(73.5-113.8)
Female	561	636.6	88.1	(81.0-95.7)	Female	97	90.6	107.0	(86.8-130.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	40	28.3	141.2	(100.8-192.2)	Male	45	62.5	72.0	(52.5-96.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	238	239.7	99.3	(87.1-112.8)	Female	61	68.3	89.3	(68.3-114.7)
Female	232	258.7	89.7	(78.5-102.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	65	51.4	126.5	(97.7-161.3)
Male	50	43.3	115.3	(85.6-152.1)	Female	50	61.0	82.0	(60.8-108.1)
Female	17	13.6	124.6	(72.6-199.5)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	440	612.3	71.9	(65.3-78.9)
Male	15	16.8	89.4	(50.0-147.5)	<u>Stomach</u>				
Female	10	14.4	69.6	(33.3-127.9)	Male	35	40.1	87.3	(60.8-121.5)
<u>Kidney & Renal Pelvis</u>					Female	28	28.9	96.9	(64.4-140.1)
Male	68	78.7	86.4	(67.1-109.5)	<u>Testis</u>				
Female	53	53.3	99.4	(74.5-130.1)	Male	27	29.1	92.9	(61.2-135.1)
<u>Larynx</u>					<u>Thyroid</u>				
Male	33	26.6	124.1	(85.4-174.3)	Male	30	27.5	109.3	(73.7-156.0)
Female	9	7.7	116.7	(53.3-221.6)	Female	75	90.5	82.8	(65.2-103.8)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	43	58.9	73.1	(52.9-98.4)	Female	157	139.6	112.4	(95.5-131.5)
Female	44	50.6	87.0	(63.2-116.8)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	2007	2250.9	89.2	(85.3-93.2)
Male	55	38.1	144.3	(108.7-187.8)	Female	2161	2327.2	92.9	(89.0-96.9)
Female	24	15.1	159.4	(102.1-237.2)					
<u>Lung and Bronchus</u>									
Male	343	313.5	109.4	(98.1-121.6)					
Female	324	327.1	99.1	(88.6-110.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Worthington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	1.6	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	7	5.4	128.6	(51.5-265.0)	Female	1	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	2.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.5	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	6	6.3	94.6	(34.5-205.9)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.2	nc	(nc-nc)
Male	2	0.8	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.4	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.5	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	15	21.7	69.2	(38.7-114.2)
Male	0	0.4	nc	(nc-nc)	Female	14	17.8	78.9	(43.1-132.3)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	0	3.0	nc	(nc-nc)					
Female	3	2.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wrentham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	10.4	115.6	(59.6-201.9)	Male	13	7.1	183.2	(97.5-313.3)
Female	11	4.2	262.2	(130.7-469.2)	Female	9	6.0	150.1	(68.5-284.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.2	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	3	1.9	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	8	6.0	133.3	(57.4-262.7)
Female	29	42.3	68.6	(46.0-98.6)	Female	3	5.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.9	nc	(nc-nc)	Male	4	4.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	18	15.2	118.1	(70.0-186.7)	Female	8	4.4	182.8	(78.7-360.1)
Female	25	15.9	157.3	(101.8-232.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	6	3.2	186.2	(68.0-405.2)
Male	3	2.8	nc	(nc-nc)	Female	2	3.7	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	36	39.8	90.4	(63.3-125.2)
Male	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.7	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.8	nc	(nc-nc)
Male	2	5.3	nc	(nc-nc)	<u>Testis</u>				
Female	3	3.3	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.8	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	6	6.0	100.6	(36.8-219.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	3.7	nc	(nc-nc)	Female	11	9.0	122.8	(61.2-219.7)
Female	3	3.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	144	143.6	100.3	(84.5-118.0)
Male	1	2.7	nc	(nc-nc)	Female	148	146.4	101.1	(85.4-118.7)
Female	1	0.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	12	19.1	62.9	(32.4-109.8)					
Female	12	19.4	62.0	(32.0-108.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Yarmouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	83	53.8	154.3	(122.9-191.3)	Male	50	27.0	185.4	(137.6-244.4)
Female	23	19.8	116.3	(73.7-174.5)	Female	29	20.1	144.4	(96.7-207.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	7.1	113.2	(48.7-223.0)	Male	7	7.7	90.8	(36.4-187.0)
Female	7	6.3	110.4	(44.2-227.5)	Female	6	6.2	96.8	(35.4-210.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	4	1.6	nc	(nc-nc)	Male	22	24.0	91.8	(57.5-139.0)
Female	153	150.9	101.4	(85.9-118.8)	Female	26	23.7	109.7	(71.6-160.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	5.1	97.5	(31.4-227.6)	Male	11	15.0	73.5	(36.7-131.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	67	69.9	95.9	(74.3-121.8)	Female	17	16.6	102.6	(59.7-164.3)
Female	62	72.3	85.7	(65.7-109.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	17	15.3	111.4	(64.8-178.3)
Male	11	12.2	90.3	(45.0-161.7)	Female	19	17.3	109.8	(66.1-171.5)
Female	5	3.9	128.9	(41.5-300.7)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	227	170.9	132.8	(116.1-151.3)
Male	4	2.5	nc	(nc-nc)	<u>Stomach</u>				
Female	3	2.0	nc	(nc-nc)	Male	12	12.1	99.1	(51.2-173.1)
<u>Kidney & Renal Pelvis</u>					Female	9	8.1	110.9	(50.6-210.5)
Male	20	20.5	97.6	(59.6-150.8)	<u>Testis</u>				
Female	12	13.8	87.3	(45.0-152.4)	Male	2	3.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	9	7.3	122.7	(56.0-233.0)	Male	1	5.1	nc	(nc-nc)
Female	3	2.0	nc	(nc-nc)	Female	12	15.1	79.6	(41.1-139.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	14	15.3	91.4	(49.9-153.4)	Female	35	33.9	103.4	(72.0-143.8)
Female	15	12.5	120.2	(67.2-198.3)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	708	624.3	113.4	(105.2-122.1)
Male	6	9.8	61.4	(22.4-133.7)	Female	598	584.1	102.4	(94.3-110.9)
Female	2	4.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	89	94.3	94.3	(75.8-116.1)					
Female	93	91.0	102.2	(82.5-125.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;